Definition and epidemiology
Cardiomegaly refers to an abnormally enlarged heart as detected by imaging, most often chest radiography. On a posteroanterior (PA) chest X-ray, cardiomegaly is defined by a cardiothoracic ratio (CTR) greater than 0.5, meaning the maximal transverse cardiac diameter exceeds half the maximal internal thoracic diameter at the level of the diaphragm. This measurement is less reliable on anteroposterior (AP) films, which magnify the cardiac silhouette.
Cardiomegaly is not a standalone diagnosis but rather a radiographic sign indicating underlying cardiac or systemic pathology. The prevalence varies widely depending on the population studied but increases with age and the burden of cardiovascular risk factors. It is more common in patients with chronic hypertension, ischemic heart disease, valvular disorders, and cardiomyopathies. In the United States and other developed countries, heart failure affects approximately 2–3% of the population, and a significant proportion of these patients demonstrate cardiomegaly on imaging.
Both men and women are affected, though specific causes may show gender predilection. For example, peripartum cardiomyopathy occurs exclusively in women, while ischemic cardiomyopathy is more common in men. Cardiomegaly may be detected incidentally in asymptomatic individuals or during evaluation of symptoms such as dyspnea, fatigue, or edema.
- Cardiomegaly is defined as cardiothoracic ratio >0.5 on PA chest X-ray; unreliable on AP films.
- Cardiomegaly is a sign, not a diagnosis—always search for the underlying cause.
- Pericardial effusion can mimic cardiomegaly; echocardiography differentiates true cardiac enlargement.
- Heart failure with reduced ejection fraction is managed with ACE-I/ARB, beta-blocker, MRA, and SGLT2 inhibitor.
- Left ventricular hypertrophy on ECG: increased voltage (Sokolow-Lyon >35 mm) and strain pattern.
- Athletic heart syndrome is physiologic and reversible with detraining; differentiate from pathologic hypertrophy.
- Most common cause of cardiomegaly in developed countries: ischemic heart disease and hypertension.
- BNP/NT-proBNP is elevated in heart failure; helps distinguish cardiac from pulmonary dyspnea.
Etiology and risk factors
Cardiomegaly arises from conditions that increase myocardial workload, damage myocardium, or cause volume or pressure overload. Major etiologies include:
Cardiac causes
- Heart failure: Both systolic and diastolic dysfunction lead to chamber dilation and/or hypertrophy
- Cardiomyopathies: Dilated cardiomyopathy (most common), hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy
- Valvular heart disease: Mitral regurgitation, aortic regurgitation, aortic stenosis, mitral stenosis (left atrial enlargement)
- Ischemic heart disease: Post-myocardial infarction ventricular remodeling
- Congenital heart disease: Atrial and ventricular septal defects, patent ductus arteriosus
- Pericardial effusion: Can mimic true cardiomegaly on chest X-ray
- Myocarditis: Viral, autoimmune, or toxic causes
Systemic and other causes
- Hypertension: Chronic pressure overload leads to left ventricular hypertrophy
- Pulmonary hypertension: Causes right ventricular hypertrophy and dilation (cor pulmonale)
- Chronic anemia: High-output state with volume overload
- Thyroid disease: Hyperthyroidism increases cardiac output; hypothyroidism may cause pericardial effusion
- Chronic kidney disease: Volume overload and hypertension
- Obesity: Associated with increased blood volume and metabolic demands
- Pregnancy: Peripartum cardiomyopathy
- Alcohol and toxins: Alcoholic cardiomyopathy, chemotherapy agents (anthracyclines, trastuzumab)
- Infiltrative diseases: Amyloidosis, hemochromatosis, sarcoidosis
Risk factors
- Advanced age
- Hypertension
- Diabetes mellitus
- Coronary artery disease
- Obesity
- Family history of cardiomyopathy
- Alcohol abuse
- Chemotherapy exposure
Pathophysiology
The heart enlarges through two principal mechanisms: hypertrophy (increased myocyte size) and dilation (chamber enlargement). These may occur alone or together depending on the underlying stimulus.
Pressure overload (e.g., hypertension, aortic stenosis) triggers concentric hypertrophy, in which myocytes add sarcomeres in parallel, thickening the ventricular wall without initially increasing chamber size. Over time, compliance decreases and diastolic dysfunction develops. If compensation fails, the chamber may dilate (eccentric hypertrophy).
Volume overload (e.g., mitral regurgitation, aortic regurgitation, high-output states) causes eccentric hypertrophy: myocytes add sarcomeres in series, lengthening and dilating the chamber to accommodate increased preload. Wall thickness may increase proportionally or remain normal.
Myocardial damage (e.g., myocardial infarction, myocarditis, toxins) impairs contractility. The ventricle dilates in an attempt to maintain stroke volume via the Frank-Starling mechanism, but systolic function declines and heart failure ensues.
At the molecular level, chronic stress activates neurohormonal pathways (renin-angiotensin-aldosterone system, sympathetic nervous system, natriuretic peptides) that initially support cardiac output but ultimately promote adverse remodeling, fibrosis, apoptosis, and progression to decompensated heart failure.
Pericardial effusion increases the cardiac silhouette on imaging without true myocardial enlargement; the effusion surrounds the heart, creating a "water bottle" shape on chest X-ray. Distinguishing true cardiomegaly from pericardial effusion is crucial and typically requires echocardiography.
Clinical features
Cardiomegaly itself is asymptomatic; clinical manifestations reflect the underlying disease and the degree of cardiac dysfunction.
Symptoms
Many patients are asymptomatic, and cardiomegaly is discovered incidentally on chest imaging. When symptoms occur, they typically include:
- Dyspnea: Exertional or at rest; orthopnea and paroxysmal nocturnal dyspnea suggest heart failure
- Fatigue and exercise intolerance: Reduced cardiac output
- Chest pain or pressure: May indicate ischemia or pericarditis
- Palpitations: Arrhythmias are common with structural heart disease
- Peripheral edema: Volume overload, right heart failure
- Abdominal distension: Ascites in advanced right heart failure
- Syncope or presyncope: Severe aortic stenosis, arrhythmias, or outflow obstruction
Signs
Physical examination findings vary by etiology but may include:
- Displaced or sustained apical impulse: Left ventricular enlargement
- Right ventricular heave: Right ventricular hypertrophy
- Jugular venous distension: Right heart failure or volume overload
- S3 gallop: Volume overload, systolic dysfunction
- S4 gallop: Diastolic dysfunction, hypertrophy
- Murmurs: Valvular disease (systolic murmur in aortic stenosis or mitral regurgitation; diastolic murmur in aortic regurgitation)
- Pulmonary rales: Pulmonary edema
- Hepatomegaly, ascites, peripheral edema: Right-sided heart failure
- Tachycardia, irregular rhythm: Atrial fibrillation or other arrhythmias
In acute decompensated heart failure, patients may present with respiratory distress, hypoxia, and hypotension (cardiogenic shock).
Diagnosis
Diagnosis of cardiomegaly is imaging-based, with further workup directed at identifying the underlying cause.
Chest radiography
PA chest X-ray is the most common initial test. Cardiomegaly is defined as cardiothoracic ratio >0.5. Specific chamber enlargement may be suggested by contour changes:
- Left ventricular enlargement: Downward and leftward displacement of the apex
- Left atrial enlargement: Double density sign, straightening of the left heart border, elevated left mainstem bronchus
- Right atrial enlargement: Prominent right heart border
- Right ventricular enlargement: Filling of retrosternal space on lateral view
Pericardial effusion produces a globular or "water bottle" cardiac silhouette.
Electrocardiography (ECG)
ECG does not diagnose cardiomegaly but may reveal:
- Left ventricular hypertrophy (LVH): Increased voltage (Sokolow-Lyon or Cornell criteria), strain pattern
- Right ventricular hypertrophy: Right axis deviation, dominant R in V1
- Atrial enlargement: P mitrale (left atrial), P pulmonale (right atrial)
- Arrhythmias, conduction delays, ischemic changes
Echocardiography
Transthoracic echocardiography (TTE) is the gold standard for assessing cardiac size, function, and structure. It evaluates:
- Chamber dimensions and wall thickness
- Systolic and diastolic function (ejection fraction, E/A ratio)
- Valvular anatomy and function
- Pericardial effusion
- Regional wall motion abnormalities
Laboratory tests
- B-type natriuretic peptide (BNP) or NT-proBNP: Elevated in heart failure
- Troponin: Myocardial injury or infarction
- Complete blood count: Anemia
- Thyroid function tests: Hyper- or hypothyroidism
- Renal function and electrolytes: Chronic kidney disease, volume status
- Liver function tests: Hepatic congestion
Advanced imaging
- Cardiac MRI: Gold standard for ventricular volumes and mass; detects fibrosis, infiltration, myocarditis
- Cardiac CT: Coronary artery disease, pericardial pathology
- Nuclear imaging: Viability, ischemia
Additional tests
- Stress testing: Coronary artery disease
- Cardiac catheterization: Hemodynamics, coronary anatomy
- Endomyocardial biopsy: Rarely needed; for suspected infiltrative disease or specific cardiomyopathies
Differential diagnosis
The differential diagnosis of cardiomegaly encompasses all conditions that enlarge the heart or mimic cardiac enlargement on imaging:
- Heart failure with reduced ejection fraction (HFrEF): Dilated cardiomyopathy from ischemic or non-ischemic causes
- Heart failure with preserved ejection fraction (HFpEF): Hypertrophy without dilation, often secondary to hypertension
- Valvular heart disease: Regurgitant lesions (mitral, aortic) cause dilation; stenotic lesions (aortic) cause hypertrophy
- Hypertensive heart disease: Long-standing hypertension with left ventricular hypertrophy
- Ischemic cardiomyopathy: Post-MI remodeling
- Dilated cardiomyopathy: Idiopathic, familial, viral, alcoholic, peripartum, chemotherapy-induced
- Hypertrophic cardiomyopathy: Asymmetric septal hypertrophy, often familial
- Restrictive cardiomyopathy: Amyloidosis, sarcoidosis, hemochromatosis, endomyocardial fibrosis
- Pericardial effusion: Mimics cardiomegaly on chest X-ray; distinguished by echocardiography
- High-output heart failure: Chronic anemia, thyrotoxicosis, arteriovenous fistulas, beriberi
- Congenital heart disease: Shunt lesions with volume overload
- Cor pulmonale: Right ventricular enlargement from chronic lung disease or pulmonary hypertension
- Myocarditis: Acute or chronic inflammatory cardiomyopathy
- Athletic heart syndrome: Physiologic hypertrophy and dilation in endurance athletes; normal function and reversible with detraining
Echocardiography, clinical context, and laboratory and advanced imaging studies usually differentiate these entities.
Management
Management of cardiomegaly focuses on treating the underlying cause and managing heart failure if present. There is no therapy for cardiomegaly itself; treatment targets the disease process driving cardiac enlargement.
General measures
- Lifestyle modification: Sodium restriction (<2–3 g/day), fluid restriction if severe heart failure, weight loss if obese, smoking cessation, alcohol limitation or abstinence
- Exercise: Moderate activity as tolerated; cardiac rehabilitation for heart failure patients
- Treat comorbidities: Optimize blood pressure, glycemic control, lipid management
Pharmacologic management
Therapy varies by etiology. For heart failure with reduced ejection fraction (HFrEF), guideline-directed medical therapy includes:
- ACE inhibitors or ARBs: Reduce afterload, slow remodeling (enalapril, lisinopril, losartan, valsartan)
- Beta-blockers: Improve survival (carvedilol, metoprolol succinate, bisoprolol)
- Mineralocorticoid receptor antagonists: Reduce mortality (spironolactone, eplerenone)
- SGLT2 inhibitors: Mortality benefit (dapagliflozin, empagliflozin)
- ARNI (angiotensin receptor-neprilysin inhibitor): Superior to ACE inhibitors in select patients (sacubitril-valsartan)
- Diuretics: Symptom relief, volume management (furosemide, torsemide, bumetanide)
- Hydralazine plus isosorbide dinitrate: Alternative vasodilator therapy, especially in African Americans or if ACE-I/ARB intolerant
- Digoxin: Symptom improvement, reduced hospitalization; no mortality benefit
- Ivabradine: If sinus rhythm, heart rate >70, and symptomatic on beta-blocker
For heart failure with preserved ejection fraction (HFpEF), treatment is largely supportive: diuretics for congestion, blood pressure control, and SGLT2 inhibitors have emerging evidence for benefit.
Valvular disease may require:
- Medical optimization of heart failure
- Surgical or percutaneous valve repair or replacement (e.g., TAVR for aortic stenosis, mitral clip for mitral regurgitation)
Hypertension: Aggressive control with antihypertensives can promote regression of left ventricular hypertrophy.
Ischemic heart disease: Revascularization (PCI or CABG) if indicated, plus antiplatelet agents, statins, and heart failure medications.
Cardiomyopathies: Disease-specific therapy (e.g., tafamidis for transthyretin amyloidosis, iron chelation for hemochromatosis, immunosuppression for sarcoidosis or giant cell myocarditis).
Device therapy
- Implantable cardioverter-defibrillator (ICD): Primary prevention in HFrEF with EF ≤35%; secondary prevention post-cardiac arrest or sustained ventricular arrhythmia
- Cardiac resynchronization therapy (CRT): Biventricular pacing for HFrEF with wide QRS (LBBB morphology preferred) and symptomatic heart failure
Surgical and advanced therapies
- Coronary revascularization: CABG for ischemic cardiomyopathy
- Valve surgery: Repair or replacement
- Ventricular assist devices (VADs): Bridge to transplant or destination therapy
- Heart transplantation: End-stage heart failure refractory to medical therapy
Monitoring
Regular follow-up with clinical assessment, echocardiography, and laboratory testing (renal function, electrolytes, BNP) guides therapy adjustment and detects complications.
Complications and prognosis
Complications
Cardiomegaly and its underlying causes can lead to serious complications:
- Heart failure: Progressive pump failure, acute decompensation, cardiogenic shock
- Arrhythmias: Atrial fibrillation, ventricular tachycardia, ventricular fibrillation, sudden cardiac death
- Thromboembolic events: Stroke, systemic embolism (especially with atrial fibrillation or dilated cardiomyopathy with low ejection fraction)
- Valvular insufficiency: Functional mitral or tricuspid regurgitation from chamber dilation
- Pulmonary hypertension: From chronic left heart disease
- Renal and hepatic dysfunction: Cardiorenal and cardiohepatic syndromes from chronic congestion and low output
- Sudden cardiac death: Particularly in hypertrophic cardiomyopathy and severe HFrEF
Prognosis
Prognosis depends on the underlying etiology, severity, and response to therapy.
Heart failure carries a 5-year mortality of approximately 50%, though modern therapies (GDMT, devices) have improved outcomes significantly. Patients with advanced heart failure (NYHA class IV) have 1-year mortality exceeding 50% without advanced therapies.
Ischemic cardiomyopathy generally has worse prognosis than non-ischemic causes, though revascularization and optimal medical therapy can improve outcomes.
Hypertrophic cardiomyopathy has variable prognosis; many patients have normal lifespan with modern management, but sudden death risk requires risk stratification and ICD consideration.
Valvular disease prognosis improves dramatically with timely surgical or percutaneous intervention.
Reversible causes (e.g., alcohol-induced, peripartum, tachycardia-induced cardiomyopathy) may show significant or complete recovery with cessation of the insult and appropriate therapy.
Early identification of the underlying cause, guideline-directed therapy, and close monitoring optimize outcomes and quality of life. Regression of cardiomegaly is possible in some conditions (hypertension, alcohol cessation, treatment of thyroid disease) but may be incomplete or impossible in others (extensive myocardial infarction, advanced amyloidosis).
ABCDE for guideline-directed medical therapy in HFrEF: ACE-inhibitor/ARB/ARNI, Beta-blocker, C — MRA (aldosterone antagonist), Diuretic, Empagliflozin (SGLT2 inhibitor)
Practice questions
1. A 58-year-old man with a history of poorly controlled hypertension presents with progressive dyspnea on exertion over 6 months. Physical examination reveals a laterally displaced apical impulse and an S4 gallop. Chest X-ray shows a cardiothoracic ratio of 0.58. ECG demonstrates increased voltage in the precordial leads and strain pattern. Echocardiography reveals concentric left ventricular hypertrophy with ejection fraction of 55%. Which of the following is the most likely diagnosis?
2. A 45-year-old woman presents with fatigue and peripheral edema 3 months postpartum. Examination reveals elevated jugular venous pressure, bibasilar rales, and a systolic murmur at the apex. Chest X-ray demonstrates cardiomegaly with pulmonary congestion. Echocardiography shows left ventricular ejection fraction of 30% with global hypokinesis and dilated left ventricle. Which of the following is the most appropriate initial pharmacologic therapy?
3. A 72-year-old man with chronic dyspnea is found to have cardiomegaly on chest X-ray. Echocardiography reveals a large pericardial effusion with diastolic collapse of the right atrium. Blood pressure is 88/60 mmHg, heart rate 110/min, and jugular venous pressure is elevated with a prominent x descent but blunted y descent. Pulsus paradoxus of 18 mmHg is noted. Which of the following is the most appropriate next step in management?
Frequently asked questions
What causes cardiomegaly?
Cardiomegaly is caused by conditions that damage the heart muscle or increase its workload, including heart failure, hypertension, valvular heart disease (especially mitral and aortic regurgitation), cardiomyopathies (dilated, hypertrophic, restrictive), ischemic heart disease, chronic anemia, thyroid disorders, and alcohol abuse. Pericardial effusion can mimic cardiomegaly on chest X-ray. The underlying cause must be identified and treated.
What are the first symptoms of cardiomegaly?
Cardiomegaly itself causes no symptoms and is often discovered incidentally on chest X-ray. Symptoms arise from the underlying heart disease and may include shortness of breath (especially with exertion or lying flat), fatigue, exercise intolerance, swelling in the legs and ankles, chest discomfort, and palpitations. Some patients remain asymptomatic for years, while others present with acute heart failure.
How is cardiomegaly diagnosed?
Cardiomegaly is diagnosed on chest X-ray when the cardiothoracic ratio exceeds 0.5 on a posteroanterior (PA) film. Echocardiography is the gold standard for confirming true cardiac enlargement, assessing chamber size, wall thickness, and function, and identifying the underlying cause. Additional tests include ECG, BNP, blood work for anemia or thyroid disease, and sometimes cardiac MRI or catheterization.
Is cardiomegaly curable?
Cardiomegaly may be reversible if the underlying cause is treated early. For example, controlling hypertension can reduce left ventricular hypertrophy, stopping alcohol can improve alcoholic cardiomyopathy, and treating thyroid disease or anemia may reverse cardiac enlargement. However, many causes (advanced heart failure, extensive myocardial infarction) cause permanent damage. Treatment focuses on slowing progression and managing symptoms.
Cardiomegaly vs cardiomyopathy — what is the difference?
Cardiomegaly is a radiographic finding (enlarged heart on imaging), not a disease. Cardiomyopathy is a disease of the heart muscle itself, classified as dilated, hypertrophic, restrictive, or arrhythmogenic. Cardiomyopathies often cause cardiomegaly, but cardiomegaly can also result from valvular disease, hypertension, ischemia, or pericardial effusion. Echocardiography and clinical context distinguish between them.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: I51.7
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.